{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T12:25:34Z","timestamp":1776947134211,"version":"3.51.4"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,7,30]]},"DOI":"10.7759\/cureus.42695","type":"journal-article","created":{"date-parts":[[2023,7,30]],"date-time":"2023-07-30T23:27:19Z","timestamp":1690759639000},"source":"Crossref","is-referenced-by-count":2,"title":["Outcomes of Fluorescence-Guided vs White Light Resection of Glioblastoma in a Single Institution"],"prefix":"10.7759","author":[{"given":"Li Siang","family":"Wong","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jerome","family":"St. George","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevin","family":"Agyemang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Athanasios","family":"Grivas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deborah","family":"Houston","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sin Yee","family":"Foo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Mullan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.15586\/codon.glioblastoma.2017.ch8","article-title":"Epidemiology and outcome of glioblastoma","volume":"20","author":"Tamimi AF","year":"2017","unstructured":"Tamimi AF, Juweid M. Epidemiology and outcome of glioblastoma. Exon Publications. 2017, 20:143-53. 10.15586\/codon.glioblastoma.2017.ch8","journal-title":"Exon Publications"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra0708126","article-title":"Malignant gliomas in adults","volume":"359","author":"Wen PY","year":"2008","unstructured":"Wen PY, Kesari S. Malignant gliomas in adults. N Engl J Med. 2008, 359:492-507. 10.1056\/NEJMra0708126","journal-title":"N Engl J Med"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1007\/s11060-011-0749-4","article-title":"Glioblastoma survival in the United States before and during the temozolomide era","volume":"107","author":"Johnson DR","year":"2012","unstructured":"Johnson DR, O'Neill BP. Glioblastoma survival in the United States before and during the temozolomide era. J Neurooncol. 2012, 107:359-64. 10.1007\/s11060-011-0749-4","journal-title":"J Neurooncol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2014.12.014","article-title":"Glioblastoma in England: 2007-2011","volume":"51","author":"Brodbelt A","year":"2015","unstructured":"Brodbelt A, Greenberg D, Winters T, Williams M, Vernon S, Collins VP. Glioblastoma in England: 2007-2011. Eur J Cancer. 2015, 51:533-42. 10.1016\/j.ejca.2014.12.014","journal-title":"Eur J Cancer"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.3171\/jns.2001.95.2.0190","article-title":"A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival","volume":"95","author":"Lacroix M","year":"2001","unstructured":"Lacroix M, Abi-Said D, Fourney DR, et al.. A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. J Neurosurg. 2001, 95:190-8. 10.3171\/jns.2001.95.2.0190","journal-title":"J Neurosurg"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.3171\/2012.8.JNS12234","article-title":"Extent of resection in patients with glioblastoma: limiting factors, perception of resectability, and effect on survival","volume":"117","author":"Orringer D","year":"2012","unstructured":"Orringer D, Lau D, Khatri S, et al.. Extent of resection in patients with glioblastoma: limiting factors, perception of resectability, and effect on survival. J Neurosurg. 2012, 117:851-9. 10.3171\/2012.8.JNS12234","journal-title":"J Neurosurg"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1097\/00006123-199803000-00017","article-title":"Intraoperative detection of malignant gliomas by 5-aminolevulinic acid-induced porphyrin fluorescence","volume":"42","author":"Stummer W","year":"1998","unstructured":"Stummer W, Stocker S, Wagner S, et al.. Intraoperative detection of malignant gliomas by 5-aminolevulinic acid-induced porphyrin fluorescence. Neurosurgery. 1998, 42:518-25. 10.1097\/00006123-199803000-00017","journal-title":"Neurosurgery"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1227\/NEU.0000000000000929","article-title":"What is the surgical benefit of utilizing 5-aminolevulinic acid for fluorescence-guided surgery of malignant gliomas?","volume":"77","author":"Hadjipanayis CG","year":"2015","unstructured":"Hadjipanayis CG, Widhalm G, Stummer W. What is the surgical benefit of utilizing 5-aminolevulinic acid for fluorescence-guided surgery of malignant gliomas?. Neurosurgery. 2015, 77:663-73. 10.1227\/NEU.0000000000000929","journal-title":"Neurosurgery"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1007\/s11060-010-0296-4","article-title":"Surgery guided by 5-aminolevulinic fluorescence in glioblastoma: volumetric analysis of extent of resection in single-center experience","volume":"102","author":"D\u00edez Valle R","year":"2011","unstructured":"D\u00edez Valle R, Tejada Solis S, Idoate Gastearena MA, Garc\u00eda de Eulate R, Dom\u00ednguez Ech\u00e1varri P, Aristu Mendiroz J. Surgery guided by 5-aminolevulinic fluorescence in glioblastoma: volumetric analysis of extent of resection in single-center experience. J Neurooncol. 2011, 102:105-13. 10.1007\/s11060-010-0296-4","journal-title":"J Neurooncol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(06)70665-9","article-title":"Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial","volume":"7","author":"Stummer W","year":"2006","unstructured":"Stummer W, Pichlmeier U, Meinel T, Wiestler OD, Zanella F, Reulen HJ. Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial. Lancet Oncol. 2006, 7:392-401. 10.1016\/S1470-2045(06)70665-9","journal-title":"Lancet Oncol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1227\/NEU.0b013e31828c3974","article-title":"Prognostic value of residual fluorescent tissue in glioblastoma patients after gross total resection in 5-aminolevulinic acid-guided surgery","volume":"72","author":"Aldave G","year":"2013","unstructured":"Aldave G, Tejada S, Pay E, Marigil M, Bejarano B, Idoate MA, D\u00edez-Valle R. Prognostic value of residual fluorescent tissue in glioblastoma patients after gross total resection in 5-aminolevulinic acid-guided surgery. Neurosurgery. 2013, 72:915-21. 10.1227\/NEU.0b013e31828c3974","journal-title":"Neurosurgery"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2016.1373","article-title":"Association of the extent of resection with survival in glioblastoma: a systematic review and meta-analysis","volume":"2","author":"Brown TJ","year":"2016","unstructured":"Brown TJ, Brennan MC, Li M, et al.. Association of the extent of resection with survival in glioblastoma: a systematic review and meta-analysis. JAMA Oncol. 2016, 2:1460-9. 10.1001\/jamaoncol.2016.1373","journal-title":"JAMA Oncol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.3171\/2012.4.JNS101702","article-title":"Extent of tumor removal and molecular markers in cerebral glioblastoma: a combined prognostic factors study in a surgical series of 105 patients","volume":"117","author":"Salvati M","year":"2012","unstructured":"Salvati M, Pichierri A, Piccirilli M, et al.. Extent of tumor removal and molecular markers in cerebral glioblastoma: a combined prognostic factors study in a surgical series of 105 patients. J Neurosurg. 2012, 117:204-11. 10.3171\/2012.4.JNS101702","journal-title":"J Neurosurg"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa043330","article-title":"Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma","volume":"352","author":"Stupp R","year":"2005","unstructured":"Stupp R, Mason WP, van den Bent MJ, et al.. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005, 352:987-96. 10.1056\/NEJMoa043330","journal-title":"N Engl J Med"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdu050","article-title":"High-grade glioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"25","author":"Stupp R","year":"2014","unstructured":"Stupp R, Brada M, van den Bent MJ, Tonn JC, Pentheroudakis G. High-grade glioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2014, 25:iii93-101. 10.1093\/annonc\/mdu050","journal-title":"Ann Oncol"},{"key":"ref16","unstructured":"NICE Guidance. Recommendations, Brain tumours (primary) and brain metastases in adults. (2022). Accessed: February 10, 2022: https:\/\/www.nice.org.uk\/guidance\/ng99\/chapter\/Recommendations."},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0808710","article-title":"IDH1 and IDH2 mutations in gliomas","volume":"360","author":"Yan H","year":"2009","unstructured":"Yan H, Parsons DW, Jin G, et al.. IDH1 and IDH2 mutations in gliomas. N Engl J Med. 2009, 360:765-73. 10.1056\/NEJMoa0808710","journal-title":"N Engl J Med"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djq497","article-title":"DNA methylation, isocitrate dehydrogenase mutation, and survival in glioma","volume":"103","author":"Christensen BC","year":"2011","unstructured":"Christensen BC, Smith AA, Zheng S, et al.. DNA methylation, isocitrate dehydrogenase mutation, and survival in glioma. J Natl Cancer Inst. 2011, 103:143-53. 10.1093\/jnci\/djq497","journal-title":"J Natl Cancer Inst"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1186\/1748-717X-6-115","article-title":"Prognostic significance of IDH-1 and MGMT in patients with glioblastoma: one step forward, and one step back?","volume":"6","author":"Combs SE","year":"2011","unstructured":"Combs SE, Rieken S, Wick W, Abdollahi A, von Deimling A, Debus J, Hartmann C. Prognostic significance of IDH-1 and MGMT in patients with glioblastoma: one step forward, and one step back?. Radiat Oncol. 2011, 6:115. 10.1186\/1748-717X-6-115","journal-title":"Radiat Oncol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa043331","article-title":"MGMT gene silencing and benefit from temozolomide in glioblastoma","volume":"352","author":"Hegi ME","year":"2005","unstructured":"Hegi ME, Diserens AC, Gorlia T, et al.. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 2005, 352:997-1003. 10.1056\/NEJMoa043331","journal-title":"N Engl J Med"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200011093431901","article-title":"Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents","volume":"343","author":"Esteller M","year":"2000","unstructured":"Esteller M, Garcia-Foncillas J, Andion E, et al.. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med. 2000, 343:1350-4. 10.1056\/NEJM200011093431901","journal-title":"N Engl J Med"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6605127","article-title":"Extent of MGMT promoter methylation correlates with outcome in glioblastomas given temozolomide and radiotherapy","volume":"101","author":"Dunn J","year":"2009","unstructured":"Dunn J, Baborie A, Alam F, et al.. Extent of MGMT promoter methylation correlates with outcome in glioblastomas given temozolomide and radiotherapy. Br J Cancer. 2009, 101:124-31. 10.1038\/sj.bjc.6605127","journal-title":"Br J Cancer"},{"key":"ref23","unstructured":"NHS. Gliolan 30mg\/ml oral solution (medac UK) 50 ml. (2023). Accessed: February 23, 2023: https:\/\/services.nhsbsa.nhs.uk\/dmd-browser\/ampp\/view\/88682."},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1111\/jcpt.12346","article-title":"Current trends in the management of glioblastoma in a French University Hospital and associated direct costs","volume":"41","author":"Henaine AM","year":"2016","unstructured":"Henaine AM, Paubel N, Ducray F, et al.. Current trends in the management of glioblastoma in a French University Hospital and associated direct costs. J Clin Pharm Ther. 2016, 41:47-53. 10.1111\/jcpt.12346","journal-title":"J Clin Pharm Ther"},{"key":"ref25","unstructured":"Healthcare Improvement Scotland. Cancer quality performance indicators (QPIs). (2021). Accessed: February 22, 2023: https:\/\/www.healthcareimprovementscotland.org\/our_work\/cancer_care_improvement\/cancer_qpis\/quality_performance_indica...."},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1016\/j.wneu.2011.02.005","article-title":"Impact of the combination of 5-aminolevulinic acid-induced fluorescence with intraoperative magnetic resonance imaging-guided surgery for glioma","volume":"76","author":"Tsugu A","year":"2011","unstructured":"Tsugu A, Ishizaka H, Mizokami Y, et al.. Impact of the combination of 5-aminolevulinic acid-induced fluorescence with intraoperative magnetic resonance imaging-guided surgery for glioma. World Neurosurg. 2011, 76:120-7. 10.1016\/j.wneu.2011.02.005","journal-title":"World Neurosurg"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1093\/noajnl\/vdaa111","article-title":"Awake craniotomy for resection of supratentorial glioblastoma: a systematic review and meta-analysis","volume":"2","author":"Zhang JJ","year":"2020","unstructured":"Zhang JJ, Lee KS, Voisin MR, Hervey-Jumper SL, Berger MS, Zadeh G. Awake craniotomy for resection of supratentorial glioblastoma: a systematic review and meta-analysis. Neurooncol Adv. 2020, 2:vdaa111. 10.1093\/noajnl\/vdaa111","journal-title":"Neurooncol Adv"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1016\/j.pdpdt.2013.03.007","article-title":"Risk factors for developing oral 5-aminolevulinic acid-induced side effects in patients undergoing fluorescence guided resection","volume":"10","author":"Chung IW","year":"2013","unstructured":"Chung IW, Eljamel S. Risk factors for developing oral 5-aminolevulinic acid-induced side effects in patients undergoing fluorescence guided resection. Photodiagnosis Photodyn Ther. 2013, 10:362-7. 10.1016\/j.pdpdt.2013.03.007","journal-title":"Photodiagnosis Photodyn Ther"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noab106","article-title":"The 2021 WHO Classification of Tumors of the Central Nervous System: a summary","volume":"23","author":"Louis DN","year":"2021","unstructured":"Louis DN, Perry A, Wesseling P, et al.. The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. Neuro Oncol. 2021, 23:1231-51. 10.1093\/neuonc\/noab106","journal-title":"Neuro Oncol"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2015.3113","article-title":"Performance status in patients with cancer","volume":"1","author":"West HJ","year":"2015","unstructured":"West HJ, Jin JO. Performance status in patients with cancer. JAMA Oncol. 2015, 1:998. 10.1001\/jamaoncol.2015.3113","journal-title":"JAMA Oncol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/152378-outcomes-of-fluorescence-guided-vs-white-light-resection-of-glioblastoma-in-a-single-institution","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T20:02:53Z","timestamp":1707508973000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/152378-outcomes-of-fluorescence-guided-vs-white-light-resection-of-glioblastoma-in-a-single-institution"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,30]]},"references-count":30,"URL":"https:\/\/doi.org\/10.7759\/cureus.42695","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7,30]]}}}